| Literature DB >> 34282361 |
Nooshin Delfan1, Hamid Galehdari1, Farideh Ghanbari Mardasi1, Rezvan Zabihi1, Tahereh Latifi Pakdehi1, Tahereh Seifi1, Nastaran Majdinasab2.
Abstract
OBJECTIVE: Multiple sclerosis (MS) is a partially heritable autoimmune disease. HLA-DR2 is the largest identified genetic risk factor for MS. The largest identified genetic risk factor is haplotype from the MHC class II HLA-DR2, which increases the disease risk. The HLA-DR2 distribution in MS patients has been confirmed, but contradictory outcomes have been found. Moreover, the HLA-DR2 effect on ethnicity and gender is unclear. There are no data regarding the HLA-DR2 (HLA-DRB1*1501-DRB5*01-DQB1*0602) association with MS in Khuzestan Province, Iran. This study aimed to investigate the association of HLA-DR2 with MS regarding both sex and ethnicity in this province. MATERIALS &Entities:
Keywords: HLA-DR2; HLA-DRB1*1501; Iran; Multiple sclerosis; PCR-SSP
Year: 2021 PMID: 34282361 PMCID: PMC8272550 DOI: 10.22037/ijcn.v14i4.18795
Source DB: PubMed Journal: Iran J Child Neurol ISSN: 1735-4668
Association of DR2 haplotype with MS in Khuzestan province
| HLA haplotypes | Patients | Controls | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype (%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 6 (3.27) | 183 | 4 (2.08) | 192 | 0.452 |
| 2 | DRB5*01--DQB1*0602- | 75 (39.26) | 191 | 73 (36.31) | 201 | 0.547 |
| 3 | DRB5*01+-DQB1*0602+ | 44 (23.78) | 185 | 34 (18.27) | 186 | 0.184 |
| 4 | DRB5*01--DQB1*0602+ | 62 (33.87) | 183 | 68 (35.23) | 193 | 0.738 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 21 (10.79) | 195 | 17 (10.30) | 165 | 0.886 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 3 (1.51) | 198 | 0 (0) | 174 | 0.103 |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 26 (13.54) | 192 | 14 (8.18) | 171 | 0.104 |
*=significant P values; Statistical significance was at p < 0.05. Values are expressed as No. (%).
Association of DR2 haplotype with Fars ethnic in MS patients of Khuzestan province
| HLA haplotypes | Patients | Controls | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype (%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 6 (5.08) | 115 | 2 (2.53) | 79 | 0.355 |
| 2 | DRB5*01--DQB1*0602- | 39 (33.91) | 115 | 26 (32.09) | 81 | 0.790 |
| 3 | DRB5*01+-DQB1*0602+ | 29 (25) | 116 | 11 (15.71) | 70 | 0.135 |
| 4 | DRB5*01--DQB1*0602+ | 40 (34.78) | 115 | 33 (42.85) | 77 | 0.259 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 12 (10.71) | 112 | 6 (7.69) | 78 | 0.484 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 2 (1.62) | 123 | 0 (0) | 79 | 0.255 |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 16 (13.11) | 122 | 5 (7.46) | 67 | 0.273 |
*=significant P values; Statistical significance was at p < 0.05. Values are expressed as No. (%).
Association of DR2 haplotype with Arab ethnic in MS patients of Khuzestan province
| HLA haplotypes | Patients | Controls | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype (%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 1 (1.40) | 71 | 0 (0) | 88 | 0.267 |
| 2 | DRB5*01--DQB1*0602- | 32 (44.44) | 72 | 34 (40.96) | 83 | 0.662 |
| 3 | DRB5*01+-DQB1*0602+ | 14 (20.58) | 68 | 15 (19.73) | 76 | 0.899 |
| 4 | DRB5*01--DQB1*0602+ | 23 (33.33) | 69 | 28 (35) | 80 | 0.831 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 7 (9.72) | 72 | 9 (10.84) | 83 | 0.819 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 1 (1.25) | 80 | 0 (0) | 89 | 0.290 |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 9 (12) | 75 | 8 (22.85) | 35 | 0.142 |
Association of HLA DR2 with EDSS in MS patients of Khuzestan province
| HLA haplotypes | EDSS 1-5 | EDSS 5-10 | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype (%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 5 (3.10) | 161 | 1 (14.28) | 7 | 0.119 |
| 2 | DRB5*01--DQB1*0602- | 55 (34.59) | 159 | 5 (62.05) | 8 | 0.108 |
| 3 | DRB5*01+-DQB1*0602+ | 41 (25.78) | 159 | 0 (0) | 8 | 0.098 |
| 4 | DRB5*01--DQB1*0602+ | 55 (34.37) | 160 | 2 (25) | 8 | 0.585 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 19 (10.79) | 176 | 0 () | 8 | 0.326 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 2 (1.15) | 173 | 1 (12.5) | 8 | 0.014* |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 25 (15.06) | 166 | 2 (25) | 8 | 0.448 |
*=significant P values; Statistical significance was at p < 0.05. Values are expressed as No. (%).
Analysis of association between HLA haplotypes and RRMS
| HLA haplotypes | RRMS | Non-RRMS | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype(%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 5 (3.10) | 161 | 1 (11.11) | 9 | 0.205 |
| 2 | DRB5*01--DQB1*0602- | 65 (3.86) | 168 | 3 (33.33) | 9 | 0.748 |
| 3 | DRB5*01+-DQB1*0602+ | 40 (24.53) | 163 | 1 (11.11) | 9 | 0.357 |
| 4 | DRB5*01--DQB1*0602+ | 56 (34.78) | 161 | 4 (44.44) | 9 | 0.555 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 20 (11.56) | 173 | 0 (0) | 9 | 0.280 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 2 (1.16) | 172 | 1 (11.11) | 9 | 0.023* |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 25 (14.88) | 168 | 2 (22.22) | 9 | 0.551 |
*=significant P values; Statistical significance was at p < 0.05. Values are expressed as No. (%).
Association of HLA haplotype with female in MS patients of Khuzestan province
| HLA haplotypes | Patients | Controls | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype (%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 6 (4.20) | 149 | 2 (20.06) | 97 | 0.396 |
| 2 | DRB5*01--DQB1*0602- | 53 (39.84) | 133 | 36(33.96) | 106 | 0.350 |
| 3 | DRB5*01+-DQB1*0602+ | 35 (23.80) | 147 | 18 (14.47) | 103 | 0.228 |
| 4 | DRB5*01--DQB1*0602+ | 48 (32.65) | 147 | 43 (40.95) | 105 | 0.176 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 14 (9.79) | 143 | 13 (10.40) | 125 | 0.869 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 3 (1.94) | 154 | 0 (0) | 107 | 0.146 |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 18 (12.16) | 148 | 7 (7.52) | 93 | 0.251 |
*=significant P values; Statistical significance was at p < 0.05. Values are expressed as No. (%).
Association of HLA haplotype with male in MS patients of Khuzestan province
| HLA haplotypes | Patients | controls | p value | |||
|---|---|---|---|---|---|---|
| posetive haplotype (%) | Total | posetive haplotype (%) | Total | |||
| 1 | DRB5*01+-DQB1*0602- | 0 (0) | 40 | 1 (3.03) | 33 | 0.268 |
| 2 | DRB5*01--DQB1*0602- | 17 (41.46) | 41 | 15 (36.58) | 41 | 0.651 |
| 3 | DRB5*01+-DQB1*0602+ | 8 (21.05) | 38 | 6 (17.14) | 35 | 0.672 |
| 4 | DRB5*01--DQB1*0602+ | 14 (35.89) | 39 | 12 (34.28) | 35 | 0.885 |
| 5 | DRB5*01+-DRB1*1501+-DQB1*0602+ | 4 (10.52) | 38 | 1 (2.50) | 40 | 0.077 |
| 6 | DRB5*01+ -DRB1*1501+ -DQB1*0602- | 0 (0) | 39 | 0 (0) | 40 | - |
| 7 | DRB5*01--DRB1*1501+- DQB1*0602+ | 8 (20) | 40 | 5 (15.62) | 32 | 0.632 |
*=significant P values; Statistical significance was at p < 0.05. Values are expressed as No. (%).